Effects of the novel water-soluble calcium antagonist (±)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride on the endothelium-independent and endothelium-dependent contraction in isolated canine cerebral arteries

Arzneimittel-Forschung/Drug Research

Volumn 46, Issue 7, 1996, Pages 663-666

  Kanda, Mamoru ^a   Shirahase, Hiroaki ^a   Wada, Katsuo ^a   Nakamura, Shohei ^a   Matsui, Hiroshi ^a   Fukata, Fumio ^a  

^a Research Laboratories   (Japan)

Author keywords

( ) 3 (4 allyl 1 piperazinyl) 2,2 dimethylpropylmethyl 1,4 dihydro 2,6 dimethyl 4 (3 nitrophenyl) 3,5 pyridinedicarboxylate dihydrochloride; calcium antagonist; CAS 117241 46 0; NKY 722, pharmacology

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; ADENOSINE DIPHOSPHATE; CALCIUM ANTAGONIST; CARBON DIOXIDE; ENDOTHELIN 1; IGANIDIPINE; NEW DRUG; NICARDIPINE; POTASSIUM CHLORIDE; PROSTAGLANDIN F2 ALPHA; SEROTONIN; THROMBOXANE A2 RECEPTOR STIMULATING AGENT;

ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; BRAIN ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; FEMALE; ISOLATED ARTERY; MALE; NONHUMAN; SMOOTH MUSCLE RELAXATION; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ADENOSINE DIPHOSPHATE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CEREBRAL ARTERIES; DIHYDROPYRIDINES; DOGS; ENDOTHELIUM, VASCULAR; FEMALE; MALE; MUSCLE CONTRACTION; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NICARDIPINE; POTASSIUM CHLORIDE; SEROTONIN;

EID: 0030014450     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Shirahase, H., Usui, H., Kurahashi, K. et al., J. Cardiovasc. Pharmacol. 10, 517 (1987)
2. Shirahase, H., Usui, H., Manabe, K. et al., J. Pharmacol. Exp. Ther. 247, 1152 (1988)
3. Katusic, Z. S., Vanhoutte, P. M., Biosignalling in Cardiac and Vascular Systems, M. Fujiwara, S. Narumiya, S. Miwa (eds.), pp. 28, Pergamon Press, Oxford (1989)
4. Wadworth, A. N., McTavsh, D., Drugs Aging 2, 262 (1992)
5. Haley, E. C., Kassel, N. F., Torner, J. C. et al., Neurology 41 (Suppl. 1), 346 (1991)
6. Kanda, M., Shirahase, H., Kurahashi, K. et al., Arzneim.-Forsch./Drug. Res. 45 (II), 831 (1995)
7. Ohue, T., Lee, K., Koshimura, K. et al., Br. J. Pharmacol. 103, 1889 (1991)
8. Takenaka, T., Usuda, S., Nomura, T. et al., Arzneim.-Forsch./Drug Res. 26, 2172 (1976)
9. Shirahase, H., Usui, H., Manabe, K. et al., J. Pharmacol. Exp. Ther. 247, 701 (1988)
10. Usui, H., Fujiwara, M., Shirahase, H. et al., Neuronal Messengers in Vascular Function, C. Owman, B. Arneklo-Nobin (eds.), pp. 537, Elsevier Science Publishers (Biomedical Division), Amsterdam (1987)